Modeling the health impact of increasing vaccine coverage and nonpharmaceutical interventions against coronavirus disease 2019 in Ghana

References

• Ghana Health Service. COVID-19 Ghana’s Outbreak Response Management Updates; 2022. [cited 2022 Apr 15]. Available from: https://ghanahealthservice.org/covid19/archive.php
   Google Scholar
• Harnack J, Leite SP, Fabrizio S, et al. Patterns of growth. Ghana: Economic Development in a Democratic Environment. International Monetary Fund; 2000. chap 3.
   Google Scholar
• Sibiri H, Zankawah SM, Prah D. Coronavirus diseases 2019 (COVID-19) response: highlights of Ghana’s scientific and technological innovativeness and breakthroughs. Ethics Med Public Health. 2020 Jul-Sep;14:100537. doi: 10.1016/j.jemep.2020.100537
   PubMedGoogle Scholar
• Asamoah JKK, Owusu MA, Jin Z, et al. Global stability and cost-effectiveness analysis of COVID-19 considering the impact of the environment: using data from Ghana. Chaos, Solitons & Fractals. 2020 Nov;140:110103.
   PubMed Web of Science ®Google Scholar
• Nkengasong JN, Ndembi N, Tshangela A, et al. COVID-19 vaccines: how to ensure Africa has access. Nature. 2020;586(7828):197–199. doi: 10.1038/d41586-020-02774-8
   PubMed Web of Science ®Google Scholar
• Quakyi NK, Agyemang Asante NA, Nartey YA, et al. Ghana’s COVID-19 response: the Black Star can do even better. BMJ Glob Health. 2021;6(3):e005569. doi: 10.1136/bmjgh-2021-005569
   PubMed Web of Science ®Google Scholar
• Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72–74. doi: 10.1016/S0140-6736(20)32623-4
   PubMed Web of Science ®Google Scholar
• Almuqrin A, Davidson AD, Williamson MK, et al. SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription. Genome Med. 2021;13(1):43. doi: 10.1186/s13073-021-00859-1.
   PubMed Web of Science ®Google Scholar
• Andoh D COVID-19 vaccination plan: Govt estimates GH¢295m for 20 million people. Graphic Online; 2021 Feb 21. cited 2021 Nov 1. Available from: https://www.graphic.com.gh/news/general-news/covid-19-vaccination-plan-govt-estimates-gh-295m-for-20-million-people.html
   Google Scholar
• Mathieu E, Ritchie H, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19) (OurWorldInData.org). Updated October; 2021 18. cited 2021 Oct 18. Available from: https://ourworldindata.org/covid-vaccinations?country=GHA
   Google Scholar
• Quashie PK, Mutungi JK, Dzabeng F, et al. Trends of SARS-CoV-2 antibody prevalence in selected regions across Ghana. Wellcome Open Res. 2021;6:173. doi: 10.12688/wellcomeopenres.16890.1
   Google Scholar
• Chibwana MG, Jere KC, Kamn’gona R, et al. High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi. Wellcome Open Res. 2020;5:199. doi: 10.12688/wellcomeopenres.16188.2
   Google Scholar
• Majiya H, Aliyu-Paiko M, Balogu VT, et al. Seroprevalence of SARS-CoV-2 in Niger state: Pilot cross-sectional study. JMIRx Med. 2023;4:e29587. doi: 10.2196/29587
   PubMedGoogle Scholar
• Uyoga S, Adetifa IMO, Karanja HK, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science. 2021 Jan 1;371(6524):79–82. doi: 10.1126/science.abe1916
   PubMed Web of Science ®Google Scholar
• Chen M, Li M, Hao Y, et al. The introduction of population migration to SEIAR for COVID-19 epidemic modeling with an efficient intervention strategy. Inf Fusion. 2020;64:252–258. doi: 10.1016/j.inffus.2020.08.002
   PubMed Web of Science ®Google Scholar
• Savvides C, Siegel R. Asymptomatic and presymptomatic transmission of SARS-CoV-2: a systematic review. medRxiv. 2020 Jun 17; 2020.06.11.20129072. doi:10.1101/2020.06.11.20129072.
   PubMedGoogle Scholar
• Mizumoto K, Kagaya K, Zarebski A, et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the diamond princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020 Mar;25(10):2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180
   PubMedGoogle Scholar
• He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020 May;26(5):672–675. doi: 10.1038/s41591-020-0869-5
   PubMed Web of Science ®Google Scholar
• University of British Columbia Department of Zoology. COVID-19 models lecture; cited 2020 Nov 15. Available from: https://www.zoology.ubc.ca/~bio301/Bio301/Lectures/Lecture1/COVID_Models.pdf
   Google Scholar
• Yi GY, Hu P, He W. Characterizing the COVID-19 dynamics with a new epidemic model: susceptible-exposed-asymptomatic-symptomatic-active-removed. Can J Stat. 2022 Jun;50(2):395–416. doi: 10.1002/cjs.11698
   PubMed Web of Science ®Google Scholar
• Ofori SK, Schwind JS, Sullivan KL, et al. Age-stratified model to assess health outcomes of COVID-19 vaccination strategies, Ghana. Emerg Infect Dis. 2023;29(2):360–370. doi: 10.3201/eid2902.221098
   PubMed Web of Science ®Google Scholar
• Tan J, Ge Y, Martinez L, et al. Transmission roles of symptomatic and asymptomatic COVID-19 cases: a modelling study. Epidemiol Infect. 2022;150:e171. doi: 10.1017/S0950268822001467
   PubMed Web of Science ®Google Scholar
• Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020 Mar 19;382(12):1177–1179. doi: 10.1056/NEJMc2001737
   PubMed Web of Science ®Google Scholar
• Zhao H, Lu X, Deng Y, et al. COVID-19: asymptomatic carrier transmission is an underestimated problem. Epidemiol Infect. 2020;148:e116. doi: 10.1017/S0950268820001235
   PubMed Web of Science ®Google Scholar
• Kenu E, Odikro MA, Malm KL, et al. Epidemiology of COVID-19 outbreak in Ghana, 2020. Ghana Med J. 2020 Dec;54(4 Suppl):5–15. doi: 10.4314/gmj.v54i4s.3
   PubMedGoogle Scholar
• Oduro-Mensah E, Tetteh J, Adomako I, et al. Clinical features of COVID-19 in Ghana: symptomatology, illness severity and comorbid non-communicable diseases. Ghana Med J. 2020 Dec;54(4 Suppl):23–32. doi: 10.4314/gmj.v54i4s.5
   PubMedGoogle Scholar
• Zhao S, Tang B, Musa SS, et al. Estimating the generation interval and inferring the latent period of COVID-19 from the contact tracing data. Epidemics. 2021;36:100482. doi: 10.1016/j.epidem.2021.100482
   PubMed Web of Science ®Google Scholar
• Xiang Y, Jia Y, Chen L, et al. COVID-19 epidemic prediction and the impact of public health interventions: a review of COVID-19 epidemic models. Infect Dis Model. 2021;6:324–342. doi: 10.1016/j.idm.2021.01.001
   PubMedGoogle Scholar
• Xin H, Li Y, Wu P, et al. Estimating the latent period of coronavirus disease 2019 (COVID-19). Clinl Infect Dis. 2021;74(9):1678–1681. doi: 10.1093/cid/ciab746
   Google Scholar
• Liu R, Leung RK, Chen T, et al. The effectiveness of age-specific isolation policies on epidemics of influenza a (H1N1) in a large city in Central South China. PloS One. 2015;10(7):e0132588. doi: 10.1371/journal.pone.0132588
   PubMed Web of Science ®Google Scholar
• Zhao ZY, Zhu YZ, Xu JW, et al. A five-compartment model of age-specific transmissibility of SARS-CoV-2. Infect Dis Poverty. 2020 Aug 26;9(1):117. doi: 10.1186/s40249-020-00735-x
   PubMed Web of Science ®Google Scholar
• Vynnycky E, White RG. An introduction to infectious disease modelling. Oxford: Oxford University Press; 2010.
   Google Scholar
• Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLOS Med. 2020;17(9):e1003346. doi: 10.1371/journal.pmed.1003346
   PubMed Web of Science ®Google Scholar
• Soetaert KE, Petzoldt T, Setzer RW. Solving differential equations in R: package deSolve. J Stat Softw. 2010;33(9):1–25. doi: 10.18637/jss.v033.i09
   PubMed Web of Science ®Google Scholar
• Abbasi Z, Zamani I, Mehra AHA, et al. Optimal Control Design of Impulsive SQEIAR Epidemic Models with Application to COVID-19. Chaos, Solitons & Fractals. 2020;139:110054. doi: 10.1016/j.chaos.2020.110054
   PubMed Web of Science ®Google Scholar
• Liu Z, Magal P, Seydi O, et al. A COVID-19 epidemic model with latency period. Infect Dis Model. 2020;5:323–337. doi: 10.1016/j.idm.2020.03.003
   PubMedGoogle Scholar
• Byrne AW, McEvoy D, Collins AB, et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open. 2020;10(8):e039856. doi: 10.1136/bmjopen-2020-039856
   PubMed Web of Science ®Google Scholar
• Cai Q, Huang D, Ou P, et al. COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020;75(7):1742–1752. doi: 10.1111/all.14309
   PubMed Web of Science ®Google Scholar
• Xing YH, Ni W, Wu Q, et al. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019. J Microbiol Immunol Infect. 2020;53(3):473–480. doi: 10.1016/j.jmii.2020.03.021
   PubMedGoogle Scholar
• Ma S, Zhang J, Zeng M, et al. Epidemiological parameters of COVID-19: case series study. J Med Internet Res. 2020 Oct 12;22(10):e19994. doi: 10.2196/19994
   PubMed Web of Science ®Google Scholar
• Tindale LC, Stockdale JE, Coombe M, et al. Evidence for transmission of COVID-19 prior to symptom onset. Elife. 2020;9:e57149. doi: 10.7554/eLife.57149
   PubMed Web of Science ®Google Scholar
• Armachie J, Adom-Konadu A, Asiamah M, et al. Impact of partial lockdown on time-dependent effective reproduction number of COVID-19 infection in Ghana: application of change point analysis. Preprints. 2021. doi: 10.20944/preprints202104.0125.v1
   Google Scholar
• Dwomoh D, Iddi S, Adu B, et al. Mathematical modeling of COVID-19 infection dynamics in Ghana: impact evaluation of integrated government and individual level interventions. Infect Dis Model. 2021;6:381–397. doi: 10.1016/j.idm.2021.01.008
   PubMedGoogle Scholar
• Bernal JL, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021;385(7):585–594. doi: 10.1056/NEJMoa2108891
   PubMed Web of Science ®Google Scholar
• Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947–953. doi: 10.1038/s41562-021-01122-8
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Pandemic planning scenarios; 2020. cited 2020 Nov 12. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html
   Google Scholar
• Iacobucci G. Covid-19: protection from two doses of vaccine wanes within six months, data suggest. BMJ. 2021;374:n2113. doi: 10.1136/bmj.n2113
   PubMedGoogle Scholar
• Good MF, Hawkes MT. The interaction of natural and vaccine-induced immunity with social distancing predicts the evolution of the COVID-19 pandemic. MBio. 2020 Oct 23;11(5):e02617–20. doi: 10.1128/mBio.02617-20
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ. 2021 Jan 1;99(1):19–33F.
   PubMed Web of Science ®Google Scholar
• Ghana Business News. Ghana’s population is 30.8 million; 2021 Sep 23. cited 2023 Dec 21. Available from: https://www.ghanabusinessnews.com/2021/09/23/ghanas-population-is-30-8-million/
   Google Scholar
• Perasso A. An introduction to the basic reproduction number in mathematical epidemiology. ESAIM: ProcS. 2018;62:123–138. doi: 10.1051/proc/201862123
   Google Scholar
• Chowell G, Hyman JM, Bettencourt LM, et al. Mathematical and statistical estimation approaches in epidemiology. Dordrecht: Springer Dordrecht; 2009. doi: 10.1007/978-90-481-2313-1
   Google Scholar
• McKay MD, Beckman RJ, Conover WJ. A comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics. 2000;42(1):55–61. doi: 10.1080/00401706.2000.10485979
   Web of Science ®Google Scholar
• Marino S, Hogue IB, Ray CJ, et al. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol. 2008 Sep 7;254(1):178–96. doi: 10.1016/j.jtbi.2008.04.011
   PubMed Web of Science ®Google Scholar
• Iooss B, Da Veiga S, Janon A, et al. Package ‘sensitivity’; cited 2023 Dec 21. Available from: https://cran.r-project.org/web/packages/sensitivity/index.html
   Google Scholar
• Gomero B Latin hypercube sampling and partial rank correlation coefficient analysis applied to an optimal control problem; cited 2023 Dec 21. Available from: https://trace.tennessee.edu/utk_gradthes/1278/
   Google Scholar
• Gathungu DK, Ojiambo VN, Kimathi MEM, et al. Modeling the effects of nonpharmaceutical interventions on COVID-19 spread in Kenya. Interdiscip Perspect Infect Dis. 2020;2020:6231461. doi: 10.1155/2020/6231461
   PubMedGoogle Scholar
• Bhowmik T, Tirtha SD, Iraganaboina NC, et al. A comprehensive analysis of COVID-19 transmission and mortality rates at the county level in the United States considering socio-demographics, health indicators, mobility trends and health care infrastructure attributes. PloS One. 2021;16(4):e0249133. doi: 10.1371/journal.pone.0249133
   PubMed Web of Science ®Google Scholar
• Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020 Aug;584(7820):257–261. doi: 10.1038/s41586-020-2405-7
   PubMed Web of Science ®Google Scholar
• Mumtaz GR, El-Jardali F, Jabbour M, et al. Modeling the impact of COVID-19 vaccination in Lebanon: a call to speed-up vaccine roll out. Vaccines. 2021;9(7):697. doi: 10.3390/vaccines9070697
   Web of Science ®Google Scholar
• Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clinl Infect Dis. 2021;73(12):2257–2264. doi: 10.1093/cid/ciab079
   PubMed Web of Science ®Google Scholar
• Giordano G, Colaneri M, Di Filippo A, et al. Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. Nat Med. 2021 Jun;27(6):993–998. doi: 10.1038/s41591-021-01334-5
   PubMed Web of Science ®Google Scholar
• Diagne ML, Rwezaura H, Tchoumi SY, et al. A mathematical model of COVID-19 with vaccination and treatment. Comput Math Methods Med. 2021;2021:1250129. doi: 10.1155/2021/1250129
   PubMed Web of Science ®Google Scholar
• Ullah S, Khan MA. Modeling the impact of non-pharmaceutical interventions on the dynamics of novel coronavirus with optimal control analysis with a case study. Chaos, Solitons & Fractals. 2020 Oct;139:110075. doi: 10.1016/j.chaos.2020.110075
   PubMed Web of Science ®Google Scholar
• Bubar KM, Reinholt K, Kissler SM, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Sci Total Environ. 2021;371(6532):916–921. doi: 10.1126/science.abe6959
   Google Scholar
• Kogan NE, Gantt S, Swerdlow D, et al. Leveraging serosurveillance and postmortem surveillance to quantify the impact of coronavirus disease 2019 in Africa. Clinl Infect Dis. 2023;76(3):424–432. doi: 10.1093/cid/ciac797
   PubMed Web of Science ®Google Scholar
• Kimani TN, Nyamai M, Owino L, et al. Infectious disease modelling for SARS-CoV-2 in Africa to guide policy: a systematic review. Epidemics. 2022;40:100610. doi: 10.1016/j.epidem.2022.100610
   PubMed Web of Science ®Google Scholar
• Adetokunboh OO, Mthombothi ZE, Dominic EM, et al. African based researchers’ output on models for the transmission dynamics of infectious diseases and public health interventions: a scoping review. PloS One. 2021;16(5):e0250086. doi: 10.1371/journal.pone.0250086
   PubMed Web of Science ®Google Scholar
• Boi-Dsane NAA, Dzudzor B, Alhassan Y, et al. Prevalence of common adverse events experienced following COVID-19 vaccination and its associated factors in Ghana: cross-sectional study design. Health Sci Rep. 2023 Jan;6(1):e1012. doi: 10.1002/hsr2.1012
   PubMedGoogle Scholar
• Song W, Yi Y. PIN20 predicting the IMPACT of vaccination strategies in the COVID-19 pandemic using a susceptible-exposed-infectious-removed (SEIR) MODEL. Value Health. 2021;24:S108. doi: 10.1016/j.jval.2021.04.579
   Web of Science ®Google Scholar